Co-reported respiratory adverse events in trastuzumab deruxtecan-associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database
{{output}}
BackgroundTrastuzumab deruxtecan (T-DXd) is an effective HER2-directed antibody-drug conjugate used across multiple solid tumors. Interstitial lung disease (ILD) and pneumonitis are well-recognized as clinically significant toxicities associated with T-DXd. Ho... ...
